TLSI
TriSalus Life Sciences, Inc.
Medical - Devices
Market Cap$142M
5Y Perf.-55.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
TLSI vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.88B
5Y Perf.-88.9%
TLSI vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | TLSI | NVCR |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $142M | $1.88B |
| Revenue (TTM) | $45M | $674M |
| Net Income (TTM) | $-39M | $-173M |
| Gross Margin | 84.6% | 75.2% |
| Operating Margin | -59.7% | -27.2% |
| Total Debt | $34M | $290M |
| Cash & Equiv. | $20M | $103M |
TLSI vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
TLSI
NVCR
| Stock | Feb 21 | May 26 | Return |
|---|---|---|---|
| TriSalus Life Scien… (TLSI) | 100 | 44.3 | -55.7% |
| NovoCure Limited (NVCR) | 100 | 11.1 | -88.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TLSI vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. TriSalus Life Sciences, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TLSI
TriSalus Life Sciences, Inc.
The Income Pick
TLSI is the clearest fit if your priority is income & stability and growth exposure.
- beta 1.36
- Rev growth 53.4%, EPS growth -47.2%, 3Y rev CAGR 53.9%
- Lower volatility, beta 1.36, current ratio 2.80x
Best for: income & stability and growth exposure
NVCR
NovoCure Limited
The Long-Run Compounder
NVCR carries the broadest edge in this set and is the clearest fit for long-term compounding.
- 31.0% 10Y total return vs TLSI's -56.7%
- -25.7% margin vs TLSI's -86.9%
- +1.0% vs TLSI's -11.5%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TLSI | 53.4% revenue growth vs NVCR's 8.3% |
| Quality / Margins | NVCR | -25.7% margin vs TLSI's -86.9% |
| Stability / Safety | TLSI | Beta 1.36 vs NVCR's 2.20 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NVCR | +1.0% vs TLSI's -11.5% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs TLSI's -110.7% |
TLSI vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGTLSI
TLSITriSalus Life Science…
0leads
NVCRNovoCure Limited
1leads
6 Total Categories
CATEGORYLEADERvs TLSIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
NVCR2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 14.9x TLSI's $45M. NVCR is the more profitable business, keeping -25.7% of every revenue dollar as net income compared to TLSI's -86.9%. On growth, TLSI holds the edge at +59.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $45M | $674M |
| EBITDAEarnings before interest/tax | -$26M | -$165M |
| Net IncomeAfter-tax profit | -$39M | -$173M |
| Free Cash FlowCash after capex | -$19M | -$48M |
| Gross MarginGross profit ÷ Revenue | +84.6% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -59.7% | -27.2% |
| Net MarginNet income ÷ Revenue | -86.9% | -25.7% |
| FCF MarginFCF ÷ Revenue | -41.9% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +59.8% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +48.8% | -100.0% |
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Valuation Metrics
NVCR leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $142M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $156M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.47x | -13.52x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.15x | 2.86x |
| Price / BookPrice ÷ Book value/share | — | 5.40x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Profitability & Efficiency
On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs TLSI's 4/9, reflecting solid financial health.
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | — | -50.8% |
| ROA (TTM)Return on assets | -110.7% | -16.5% |
| ROICReturn on invested capital | — | -16.4% |
| ROCEReturn on capital employed | -143.4% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | $14M | $187M |
| Cash & Equiv.Liquid assets | $20M | $103M |
| Total DebtShort + long-term debt | $34M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -9.61x | -96.80x |
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TLSI five years ago would be worth $4,671 today (with dividends reinvested), compared to $852 for NVCR. Over the past 12 months, NVCR leads with a +1.0% total return vs TLSI's -11.5%. The 3-year compound annual growth rate (CAGR) favors TLSI at -23.9% vs NVCR's -38.1% — a key indicator of consistent wealth creation.
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | -25.4% | +25.7% |
| 1-Year ReturnPast 12 months | -11.5% | +1.0% |
| 3-Year ReturnCumulative with dividends | -55.9% | -76.2% |
| 5-Year ReturnCumulative with dividends | -53.3% | -91.5% |
| 10-Year ReturnCumulative with dividends | -56.7% | +31.0% |
| CAGR (3Y)Annualised 3-year return | -23.9% | -38.1% |
Evenly matched — TLSI and NVCR each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TLSI and NVCR each lead in 1 of 2 comparable metrics.
Risk & Volatility
TLSI is the less volatile stock with a 1.36 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 82.2% from its 52-week high vs TLSI's 57.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.36x | 2.20x |
| 52-Week HighHighest price in past year | $7.95 | $20.06 |
| 52-Week LowLowest price in past year | $3.42 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +57.2% | +82.2% |
| RSI (14)Momentum oscillator 0–100 | 57.8 | 67.5 |
| Avg Volume (50D)Average daily shares traded | 167K | 1.6M |
Evenly matched — TLSI and NVCR each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates TLSI as "Buy" and NVCR as "Buy". Consensus price targets imply 130.8% upside for TLSI (target: $11) vs 103.1% for NVCR (target: $34).
| Metric | TLSITriSalus Life Sci… | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.50 | $33.50 |
| # AnalystsCovering analysts | 2 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 1 of 6 categories — strongest in Valuation Metrics. 4 categories are tied.
Best OverallNovoCure Limited (NVCR)Leads 1 of 6 categories
Loading custom metrics...
TLSI vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is TLSI or NVCR a better buy right now?
For growth investors, TriSalus Life Sciences, Inc.
(TLSI) is the stronger pick with 53. 4% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate TriSalus Life Sciences, Inc. (TLSI) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — TLSI or NVCR?
Over the past 5 years, TriSalus Life Sciences, Inc.
(TLSI) delivered a total return of -53. 3%, compared to -91. 5% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +31. 0% versus TLSI's -56. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — TLSI or NVCR?
By beta (market sensitivity over 5 years), TriSalus Life Sciences, Inc.
(TLSI) is the lower-risk stock at 1. 36β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 62% more volatile than TLSI relative to the S&P 500.
04Which is growing faster — TLSI or NVCR?
By revenue growth (latest reported year), TriSalus Life Sciences, Inc.
(TLSI) is pulling ahead at 53. 4% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: NovoCure Limited grew EPS 21. 8% year-over-year, compared to -47. 2% for TriSalus Life Sciences, Inc.. Over a 3-year CAGR, TLSI leads at 53. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — TLSI or NVCR?
NovoCure Limited (NVCR) is the more profitable company, earning -20.
8% net margin versus -154. 3% for TriSalus Life Sciences, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -59. 7% for TLSI. At the gross margin level — before operating expenses — TLSI leads at 84. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — TLSI or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is TLSI or NVCR better for a retirement portfolio?
For long-horizon retirement investors, TriSalus Life Sciences, Inc.
(TLSI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TLSI: -56. 7%, NVCR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between TLSI and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TLSI is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(TLSI: 59.8% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.